SCHEMBL9084

SCHEMBL9084

O=C1CC=CC=C1C(=O)OO

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911174 0.86 CRHBP (0.31) CRHBPCRHR2
SCHEMBL7767135 0.84 CRHBP (0.42) CRHBPCRHR2
SCHEMBL3692750 0.81 ALDH1A1 (0.32)
SCHEMBL277725 0.81 TSHR (0.34)
SCHEMBL11206256 0.79 TDP1 (0.39)
SCHEMBL5153493 0.79 TSHR (0.40)
SCHEMBL1407974 0.79 TP53 (0.34)
SCHEMBL3916283 0.79
SCHEMBL9459241 0.79
SCHEMBL16102240 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973873-A2 PROCESSES FOR THE PREPARATION OF MODAFINIL AND ANALOGS THEREOF Mallinckrodt Inc. (US) 2008-10-01 EP claimed
WO-2007070238-A2 PROCESSES FOR THE PREPARATION OF MODAFINIL AND ANALOGS THEREOF MALLINCKRODT INC. (US) 2007-06-21 WO claimed
EP-4329889-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2024-03-06 EP disclosed
EP-4182316-A1 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 Vanderbilt University (US) 2023-05-24 EP disclosed
WO-2022015988-A1 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2022-01-20 WO disclosed
EP-3678663-A1 COMBINATION THERAPY FOR TREATING CANCER Epizyme, Inc. (US) 2020-07-15 EP disclosed
WO-2019050924-A1 COMBINATION THERAPY FOR TREATING CANCER Epizyme, Inc. (US) 2019-03-14 WO disclosed
EP-3439655-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS Quretech Bio AB (SE) 2019-02-13 EP disclosed
WO-2017175182-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS QURETECH BIO AB (SE) 2017-10-12 WO disclosed
EP-2951170-A2 FLAP MODULATORS Janssen Pharmaceutica, N.V. (BE) 2015-12-09 EP disclosed
WO-2014121055-A2 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed
WO-2013032608-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2013-03-07 WO disclosed
EP-2485590-A1 PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE Merck Sharp & Dohme Corp. (US) 2012-08-15 EP disclosed
WO-2011044184-A1 PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2011-04-14 WO disclosed